We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Microfluidics Device Detects Cancer Cells in Blood

By LabMedica International staff writers
Posted on 12 Mar 2019
The ability to successfully isolate cancer cells is a crucial step in enabling liquid biopsy where cancer could be detected through a simple blood draw. More...
This would eliminate the discomfort and cost of tissue biopsies, which use needles or surgical procedures as part of cancer diagnosis.

Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs. However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities.

Bioengineers collaborating with those at the University of Illinois Cancer Center (Chicago, IL, USA) have developed a device that can isolate individual cancer cells from patient blood samples. The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans.

The scientists 'spiked' 5 mL samples of healthy blood with 10 small-cell-lung cancer cells and then ran the blood through their device. They were able to recover 93% of the cancer cells using the microfluidic device. Previously developed microfluidics devices designed to separate circulating tumor cells from blood had recovery rates between 50% and 80%. When they ran eight samples of blood taken from patients diagnosed with non-small-cell lung cancer, they were able to separate cancer cells from six of the samples using the microfluidic device, while none for five healthy control subjects.

Ian Papautsky, PhD, a Professor of Bioengineering and senior author of the study, said, “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses 'sticky' tags that capture the right cell type as it goes by. Affinity separation also requires a lot of advanced purification work which size separation techniques don't need. Without having to dilute, the time to run samples is shorter and so is preparation time.” They used whole blood in their experiments as well as blood diluted just three times, which is low compared to other protocols for cell separation using devices based on inertial migration. The study was published on February 25, 2019, in the journal Microsystems & Nanoengineering.

Related Links:
University of Illinois Cancer Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.